Analysts have been busy running the rule over several ASX shares this week.
Let's see what they are saying about these shares, courtesy of The Bull. Here's what you need to know:
Image source: Getty Images
BHP Group Ltd (ASX: BHP)
The team at MPC Markets has named this mining giant as a hold this week.
While it is a fan of BHP, it appears to be waiting for a pullback before recommending its shares as a buy. It said:
The global miner delivered a strong half year result in fiscal year 2026. Copper delivered the majority of earnings for the first time in the company's modern history. The dividend was above expectations. The balance sheet is in good shape. The conflict in Iran has rattled commodity markets, and BHP shares have fallen heavily.
Most of BHP's output goes to Asia, not through the Strait of Hormuz. The market is selling the ticker, not the fundamentals. We suggest adding on weakness, and holding for an upgrade when the conflict ends.
Commonwealth Bank of Australia (ASX: CBA)
Over at Sanlam Private Wealth, it has named this banking giant as a sell this week.
Although CBA is a high-quality bank, it isn't a fan of its valuation. This is particularly the case given how it believes rising interest rates could slow the global economy and credit growth. It explains:
The bank is a quality company and a staple in investor portfolios. It has established a strong track record of performance over many years. The company delivered a 5 per cent increase in statutory net profit after tax in the first half of fiscal year 2026.
However, the dividend yield was trading below 3 per cent on March 26, so better income is available elsewhere. The conflict in Iran suggests a possibly slowing global economy likely to impact credit growth in Australia's higher interest rate environment. CBA is trading at a premium to peers, so it may be time to consider reducing exposure in this volatile environment.
Pro Medicus Ltd (ASX: PME)
One ASX share that MPC Markets is positive on is Pro Medicus. It has named the health imaging technology company's shares as a buy.
MPC Markets thinks investors should be buying the dip after recent share price weakness. It said:
The company provides medical imaging software and services to hospitals and healthcare groups across the world. Its software has quietly become the dominant choice across some of the largest hospital networks in the United States. The product is faster, more scalable and modern than what its competitors offer. Artificial intelligence is built in, so it complements the business.
The share price plunge has been driven by broad technology sentiment as opposed to issues with the business. Earnings are still growing and the company still wins major new hospital contracts. In our view, the market has handed investors an appealing entry point into one of the best software businesses on the ASX. We retain our buy recommendation.
